Eli Lilly wants to gain on Novo Nordisk's obesity lead
![Photo: Mike Blake/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13977900.ece/ALTERNATES/schema-16_9/20220211-205515-4-7741x4348ma.jpg)
While Novo Nordisk has taken the center stage of the obesity market in the US, the Danish pharmaceutical firm’s archrival there, Eli Lilly, is plotting ways to commercially challenge Wegovy with its own candidate, tirzepatide.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk remains coy over Wegovy blockbuster potential
For subscribers
Novo Nordisk upgrades full-year guidance
For subscribers